Hikma adds two biosimilars to portfolio with Gedeon Richter agreement

(Alliance News) - Hikma Pharmaceuticals PLC said Thursday it has signed an exclusive license ...

Alliance News 9 December, 2021 | 9:25AM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - Hikma Pharmaceuticals PLC said Thursday it has signed an exclusive license agreement with Hungarian multinational pharmaceutical and biotechnology firm Gedeon Richter PLC to commercialise denosumab.

The licence will cover Gedeon's two biosimilar products with Prolia and Xgeva in the US.

"The products are used for the treatment of osteoporosis and fractures due to bone metastasis respectively and are currently in global Phase 1 and Phase 3 clinical studies," Hikma said.

It added: "According to the agreement, Richter is responsible for the development of the products - to conduct both Phase 1 and Phase 3 global clinical studies - and will supply finished commercial products for the US market. Hikma is responsible for registering the products with the US Food & Drug Administration and will have exclusive rights to commercialise them in the US."

As part of the deal, Gedeon will make upfront payment, as well as certain milestone payments linked to reaching defined development stages, totalling a double-digit million US dollar figure.

Hikma Chief Executive Siggi Olafsson said: "Biosimilars are a growing area of interest for Hikma and we are delighted to add two new products to our portfolio, building on our position as one of the leading suppliers of sterile injectable medicines in the US.

"This key collaboration is highly complementary and strengthens our US oncology and auto-immune offerings. Gedeon Richter brings strong technical capabilities for biological products which, combined with our well-established commercial presence in the US market makes for a partnership with exciting potential."

Shares in Hikma Pharmaceuticals were trading flat in London on Thursday morning at 2,267.00 pence each.

By Paul McGowan; paulmcgowan@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Hikma Pharmaceuticals PLC 1,854.00 GBX 2.26 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures